Vertex Pharmaceuticals (VRTX) Q4 Earnings Miss Estimates

分组1 - Vertex Pharmaceuticals reported quarterly earnings of $5.03 per share, missing the Zacks Consensus Estimate of $5.07 per share, but showing an increase from $3.98 per share a year ago, resulting in an earnings surprise of -0.74% [1] - The company posted revenues of $3.19 billion for the quarter ended December 2025, surpassing the Zacks Consensus Estimate by 0.70%, and showing an increase from year-ago revenues of $2.91 billion [2] - Vertex has surpassed consensus EPS estimates two times over the last four quarters and topped consensus revenue estimates three times during the same period [2] 分组2 - The stock's immediate price movement will depend on management's commentary during the earnings call, with Vertex shares having added about 1.7% since the beginning of the year compared to the S&P 500's gain of 1.4% [3] - The current consensus EPS estimate for the coming quarter is $4.65 on revenues of $3.11 billion, and for the current fiscal year, it is $19.92 on revenues of $12.91 billion [7] - The Medical - Biomedical and Genetics industry, to which Vertex belongs, is currently in the top 36% of over 250 Zacks industries, indicating a favorable outlook for the sector [8]